Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

Trial Profile

Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs LY 2795050 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 30 Mar 2016 Status changed from active, no longer recruiting to discontinued as the principal investigator Dr. Alex Neumeister left NYU in March 2015 as reported by ClinicalTrials.gov.
    • 26 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top